Finally, in light of the proposed inhibitory role for 5-HT1F in glucagon secretion, the 5-HT1F receptor agonist, Lasmiditan, which is currently in Phase III clinical trials for migraines, could be a potential therapeutic target to suppress glucagon release in diabetics (Reuter et al., 2015; Almaca et al., 2016; Barbanti et al., 2017). Here, GCG is linked to migraine disorder.